Metastatic infection during Staphylococcus aureus bacteremia
- PMID: 31676266
- DOI: 10.1016/j.jiac.2019.10.003
Metastatic infection during Staphylococcus aureus bacteremia
Abstract
Staphylococcus aureus causes various infections, including skin and soft tissue infections and pneumonia via both, community-associated and nosocomial infection. These infectious diseases can lead to bacteremia, and may subsequently result in metastatic infections in several cases. Metastatic infections are critical complications in patients with S. aureus bacteremia, since the optimal duration of the antimicrobial treatment differs in patients with and without metastatic infection. Notably, two weeks of antimicrobial treatment is recommended in case of uncomplicated S. aureus bacteremia, whereas in patients with S. aureus bacteremia-associated endocarditis or vertebral osteomyelitis, six weeks of antimicrobial administration is vital. In addition, misdiagnosis or insufficient treatment in metastatic infection is associated with poor prognosis, functional disability, and relapse. Although echocardiography is recommended to examine endocarditis in the patients with S. aureus bacteremia, it remains unclear which patients should undergo additional examinations, such as CT and MRI, to detect the presence of other metastatic infections. Clinical studies have revealed that permanent foreign body and persistent bacteremia are predictive factors for metastatic infections, and experimental studies have demonstrated that the virulence factors of S. aureus, such as fnbA and clfA, are associated with endocarditis; however, these factors are not proven to increase the risk of metastatic infections. In this review, we assessed the incidence, predictive factors, diagnosis, and treatment for metastatic infections during S. aureus bacteremia.
Keywords: Bacteremia; Metastatic infection; Predictive factor; Staphylococcus aureus; Virulence factor.
Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Tetsuya Horino received speaker honoraria from MSD K.K., Astellas Pharma Inc., Torii Pharmaceutical Co. Ltd., Pfizer Japan, Inc., Taisho Toyama Pharmaceutical Co., Ltd., and Dainippon Sumitomo Pharma Co., Ltd., Seiji Hori has received speaker honoraria from KYORIN Pharmaceutical Co., Ltd. and MeijiSeika Pharma Co., Ltd.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
